PURPOSE: The purpose of this is to study long-time results of surgery for primary aldosteronism. MATERIALS AND METHODS: Thirty patients operated on for primary aldosteronism were followed for an average of 7 years. All but five required potassium substitution. Systolic as well as diastolic hypertension (mean 157/93 mmHg) was present necessitating one to five antihypertensive drugs daily (mean 2.33). Preoperative indications for surgery included presumed adenoma (aldosterone-producing adenoma (APA)) or in one case unilateral dominance of hyperplasia. RESULTS: Histopathology was classified into adenoma (n = 9), dominant nodule (n = 16), and general hyperplasia without dominating nodules (n = 5), demonstrating a higher frequency of hyperplasia than anticipated. Long-term results revealed well-controlled blood pressure (BP; mean 134/80 mmHg). Antihypertensive medication was reduced (average of 1.78 per day), but only 36% of the patients were taken off these drugs completely. S-Aldosterone was normalized. All but one (a recurrence) were normokalemic without potassium substitution at follow-up. The APA group needed less medication (median 0.5 vs. 1.5 and 2 per day) and more patients in this group were totally medication free (50%). Two recurrences occurred in the group with general hyperplasia without dominating nodules. CONCLUSION: Nodular hyperplasia is more common than anticipated. Hypersecretion of aldosterone may be released from a large nodule identified as an adenoma, as well as from a generally hyperplastic gland that has not been identified as such. Nevertheless, surgery for lateralized disease results in good long-term control of BP with less antihypertensive medication. However, patients with dominant nodule or general hyperplasia without dominating nodules need more postoperative treatment than patients with APA. The majority of patients do not achieve normotension without medications, but they do become normokalemic.
PURPOSE: The purpose of this is to study long-time results of surgery for primary aldosteronism. MATERIALS AND METHODS: Thirty patients operated on for primary aldosteronism were followed for an average of 7 years. All but five required potassium substitution. Systolic as well as diastolic hypertension (mean 157/93 mmHg) was present necessitating one to five antihypertensive drugs daily (mean 2.33). Preoperative indications for surgery included presumed adenoma (aldosterone-producing adenoma (APA)) or in one case unilateral dominance of hyperplasia. RESULTS: Histopathology was classified into adenoma (n = 9), dominant nodule (n = 16), and general hyperplasia without dominating nodules (n = 5), demonstrating a higher frequency of hyperplasia than anticipated. Long-term results revealed well-controlled blood pressure (BP; mean 134/80 mmHg). Antihypertensive medication was reduced (average of 1.78 per day), but only 36% of the patients were taken off these drugs completely. S-Aldosterone was normalized. All but one (a recurrence) were normokalemic without potassium substitution at follow-up. The APA group needed less medication (median 0.5 vs. 1.5 and 2 per day) and more patients in this group were totally medication free (50%). Two recurrences occurred in the group with general hyperplasia without dominating nodules. CONCLUSION:Nodular hyperplasia is more common than anticipated. Hypersecretion of aldosterone may be released from a large nodule identified as an adenoma, as well as from a generally hyperplastic gland that has not been identified as such. Nevertheless, surgery for lateralized disease results in good long-term control of BP with less antihypertensive medication. However, patients with dominant nodule or general hyperplasia without dominating nodules need more postoperative treatment than patients with APA. The majority of patients do not achieve normotension without medications, but they do become normokalemic.
Authors: Celestino Pio Lombardi; Marco Raffaelli; Carmela De Crea; Vittoria Rufini; Giorgio Treglia; Rocco Bellantone Journal: Langenbecks Arch Surg Date: 2007-01-23 Impact factor: 3.445
Authors: Michael Stowasser; Richard D Gordon; Thanuja G Gunasekera; Diane C Cowley; Gregory Ward; Colin Archibald; B Mark Smithers Journal: J Hypertens Date: 2003-11 Impact factor: 4.844
Authors: Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Tony C Pang; Chris Bambach; Judith C Monaghan; Stan B Sidhu; Alex Bune; Leigh W Delbridge; Mark S Sywak Journal: ANZ J Surg Date: 2007-09 Impact factor: 1.872
Authors: Christina Westerdahl; Anders Bergenfelz; Anders Isaksson; Christina Nerbrand; Stig Valdemarsson Journal: Scand J Prim Health Care Date: 2011-03 Impact factor: 2.581
Authors: Omair A Shariq; Kabir Mehta; Geoffrey B Thompson; Melanie L Lyden; David R Farley; Irina Bancos; Benzon M Dy; William F Young; Travis J McKenzie Journal: World J Surg Date: 2019-10 Impact factor: 3.352
Authors: Minna Soinio; Anna-Kaarina Luukkonen; Marko Seppänen; Jukka Kemppainen; Janne Seppänen; Juha-Pekka Pienimäki; Helena Leijon; Tiina Vesterinen; Johanna Arola; Eila Lantto; Semi Helin; Ilkka Tikkanen; Saara Metso; Tuomas Mirtti; Ilkka Heiskanen; Leena Norvio; Mirja Tiikkainen; Tuula Tikkanen; Timo Sane; Matti Välimäki; Celso E Gomez-Sanchez; Ilkka Pörsti; Pirjo Nuutila; Pasi I Nevalainen; Niina Matikainen Journal: Eur J Endocrinol Date: 2020-12 Impact factor: 6.664